Phase II study of amonafide in patients with recurrent glioma

Ralph Levitt; Jan C. Buckner; Terrence L. Cascino; Patrick A. Burch; Roscoe F. Morton; Mark W. Westberg; Richard M. Goldberg; James G. Gallagher; Judith R. O'Fallon; Bernd W. Scheithauer

doi:10.1007/BF01058464

Phase II study of amonafide in patients with recurrent glioma

Ralph Levitt, Jan C. Buckner, Terrence L. Cascino, Patrick A. Burch, Roscoe F. Morton, Mark W. Westberg, Richard M. Goldberg, James G. Gallagher, Judith R. O'Fallon, Bernd W. Scheithauer

Medical Oncology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

Original language	English (US)
Pages (from-to)	87-93
Number of pages	7
Journal	Journal of neuro-oncology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1007/BF01058464
State	Published - Feb 1995

Keywords

amonafide
astrocytoma
brain neoplasm
chemotherapy
glioma

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/BF01058464

Cite this

@article{b7be7a545a2a4b0db8bd65e89c09fd6b,

title = "Phase II study of amonafide in patients with recurrent glioma",

abstract = "Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.",

keywords = "amonafide, astrocytoma, brain neoplasm, chemotherapy, glioma",

author = "Ralph Levitt and Buckner, {Jan C.} and Cascino, {Terrence L.} and Burch, {Patrick A.} and Morton, {Roscoe F.} and Westberg, {Mark W.} and Goldberg, {Richard M.} and Gallagher, {James G.} and O'Fallon, {Judith R.} and Scheithauer, {Bernd W.}",

year = "1995",

month = feb,

doi = "10.1007/BF01058464",

language = "English (US)",

volume = "23",

pages = "87--93",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II study of amonafide in patients with recurrent glioma

AU - Levitt, Ralph

AU - Buckner, Jan C.

AU - Cascino, Terrence L.

AU - Burch, Patrick A.

AU - Morton, Roscoe F.

AU - Westberg, Mark W.

AU - Goldberg, Richard M.

AU - Gallagher, James G.

AU - O'Fallon, Judith R.

AU - Scheithauer, Bernd W.

PY - 1995/2

Y1 - 1995/2

N2 - Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

AB - Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

KW - amonafide

KW - astrocytoma

KW - brain neoplasm

KW - chemotherapy

KW - glioma

UR - http://www.scopus.com/inward/record.url?scp=0028947130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028947130&partnerID=8YFLogxK

U2 - 10.1007/BF01058464

DO - 10.1007/BF01058464

M3 - Article

C2 - 7623074

AN - SCOPUS:0028947130

SN - 0167-594X

VL - 23

SP - 87

EP - 93

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 1

ER -

Phase II study of amonafide in patients with recurrent glioma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this